Acromegaly pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 96 pages | ID: A3E4D0A2614CEN
VPAResearch

Abstracts

2020 Acromegaly PIPELINE HIGHLIGHTS
Acromegaly is one of the widely researched conditions during 2020 with 22 companies actively focusing on realizing pipeline’s potential. Development of Acromegaly medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Acromegaly market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Acromegaly.

Good progress is anticipated during 2020 and 2021 with Acromegaly pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Acromegaly pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Acromegaly DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Acromegaly pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Acromegaly pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Acromegaly presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Acromegaly pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Acromegaly DRUG PROFILES
Acromegaly development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Acromegaly COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Acromegaly drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Acromegaly. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 22 Acromegaly companies including company overview, key snapshot, contact information, and their strategies on accelerating Acromegaly pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Amryt Pharma plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, Ascil Proyectos SL, Auritec Pharmaceuticals Inc, Camurus AB, Chiasma Inc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Dauntless Pharmaceuticals Inc, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals Co Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, Midatech Pharma Plc, Ono Pharmaceutical Co Ltd, OPKO Health Inc, Rani Therapeutics, Strongbridge Biopharma plc

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Acromegaly
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO ACROMEGALY

1.1 Acromegaly- Disease overview
1.2 Acromegaly- Market Size
1.3 Acromegaly- Companies Involved

2. ACROMEGALY PIPELINE SNAPSHOT- 2020

2.1 Acromegaly Pipeline by Phase
2.2 Acromegaly Pipeline by Mechanism of Action
2.3 Acromegaly Pipeline by Route of Administration
2.4 Acromegaly Pipeline- New Molecular Entities
2.5 Acromegaly Pipeline- Orphan Drug Designation/ Special Designation

3. ACROMEGALY DRUG PROFILES

3.1 Current Status
3.2 Acromegaly Drug Snapshot
3.3 Acromegaly Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Amryt Pharma plc Acromegaly Pipeline Insights and Clinical Trials
4.2 Antisense Therapeutics Ltd Acromegaly Pipeline Insights and Clinical Trials
4.3 Aquestive Therapeutics Inc Acromegaly Pipeline Insights and Clinical Trials
4.4 Ascil Proyectos SL Acromegaly Pipeline Insights and Clinical Trials
4.5 Auritec Pharmaceuticals Inc Acromegaly Pipeline Insights and Clinical Trials
4.6 Camurus AB Acromegaly Pipeline Insights and Clinical Trials
4.7 Chiasma Inc Acromegaly Pipeline Insights and Clinical Trials
4.8 Crinetics Pharmaceuticals Inc Acromegaly Pipeline Insights and Clinical Trials
4.9 Daewoong Pharmaceutical Co Ltd Acromegaly Pipeline Insights and Clinical Trials
4.10 Dauntless Pharmaceuticals Inc Acromegaly Pipeline Insights and Clinical Trials
4.11 DexTech Medical AB Acromegaly Pipeline Insights and Clinical Trials
4.12 Enesi Pharma Ltd Acromegaly Pipeline Insights and Clinical Trials
4.13 Foresee Pharmaceuticals Co Ltd Acromegaly Pipeline Insights and Clinical Trials
4.14 GeneScience Pharmaceuticals Co Ltd Acromegaly Pipeline Insights and Clinical Trials
4.15 GlyTech Inc Acromegaly Pipeline Insights and Clinical Trials
4.16 Ionis Pharmaceuticals Inc Acromegaly Pipeline Insights and Clinical Trials
4.17 Italfarmaco SpA Acromegaly Pipeline Insights and Clinical Trials
4.18 Midatech Pharma Plc Acromegaly Pipeline Insights and Clinical Trials
4.19 Ono Pharmaceutical Co Ltd Acromegaly Pipeline Insights and Clinical Trials
4.20 OPKO Health Inc Acromegaly Pipeline Insights and Clinical Trials
4.21 Rani Therapeutics Acromegaly Pipeline Insights and Clinical Trials
4.22 Strongbridge Biopharma plc Acromegaly Pipeline Insights and Clinical Trials

5. ACROMEGALY MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information